Downloading...
Download

Psychedelics

ATAI Life Sciences | ATAI | Long at $1.30ATAI Life Sciences NASDAQ:ATAI , a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, is fast approaching my selected historical simple moving average (SMA). Often, but not always, the closer the price gets to this line, the higher chance there is for a fast upward move. In anticipation of this move, NASDAQ:ATAI is in a personal buy zone at $1.30. A word of caution: this is a pure technical analysis play and this company is not expected to be profitable for many, many years... Target #1 = $1.75 Target #2 = $2.50 Target #3 = $2.95
NASDAQ:ATAILong
by WorthlessViews
2
ATAI - 2 potential paths to $5After successfully surpassing the previous swing high with considerable volume, attaining a fresh 52-week peak of $2.85, and witnessing the 50-day moving averages intersecting the 150 and 200 SMAs, ATAI appears poised for a reversal from its downtrend. **Potential Scenarios:** **Scenario 1: Triangular Consolidation (Orange)** ATAI may undergo consolidation within a triangular pattern marked by points A to E. This consolidation phase could indicate a period of indecision in the market as buyers and sellers balance their positions. Typically, triangular patterns suggest that volatility is decreasing, leading to an impending breakout. If this pattern unfolds as expected, a breakout is anticipated around mid-August, potentially triggering a significant move in the stock price. **Scenario 2: Corrective Pattern (Yellow)** Alternatively, the stock might experience a corrective phase represented by an A-B-C pattern. This corrective pattern could indicate a temporary pullback or retracement within the broader uptrend. Such corrections often serve to alleviate overbought conditions and provide an opportunity for new buyers to enter the market. In this scenario, ATAI is expected to establish a higher low by mid-August, reinforcing the bullish momentum and setting the stage for further upside potential. **Price Targets:** Anticipated Fibonacci targets include 1.414 ($4.45) or 1.616 ($5.54) to be achieved by year-end. These Fibonacci extensions are commonly used by traders to identify potential levels of resistance or support based on previous price movements. Additionally, a more ambitious target exceeding $15 within the next few years is also envisaged. This long-term target reflects the potential for ATAI to capitalize on emerging trends and developments within its industry, driving sustained growth and shareholder value over time.
NASDAQ:ATAILong
by joshuashepherd877
2
Compass Pathways Wave Analysis: Huge Moves aheadCompass Pathways appears to have completed an impulsive 5-wave move to the upside, signaling significant strength in its recent price action. The peak of this move, reaching $12.75, is notably identified as the B wave within an extended flat correction, potentially forming part of a larger 5-wave pattern. In anticipation of a corrective phase, I anticipate a retracement towards the 0.618 - 0.65 Fibonacci ratio. This level coincides with a point of demand established in May 2022, which has historically served as a robust support level. Therefore, I am targeting a correction to the range of $6.86-7.06, presenting a compelling buying opportunity. This represents a potential decrease of approximately 30.7% to 29.1% from the current price of $9.90. Looking ahead, my projections for subsequent waves are as follows: Low: $21.07 (+112.8%) Medium: $29.68 (+199.8%) High: $41.80 (+322.2%) Moonshot: $120 (+1,111.1%) It's essential to note that the realization of these targets will be contingent upon the outcome of Compass Pathways' significant psilocybin phase 3 trial, slated for release by year-end. Regardless of the trial's results, I anticipate a substantial increase in price leading up to the release date, driven by market anticipation and sentiment. In summary, while Compass Pathways demonstrates considerable strength in its recent price movements, caution is advised as the stock may undergo a corrective phase towards identified support levels before potentially resuming its upward trajectory, influenced by the impending trial results.
NASDAQ:CMPSLong
by joshuashepherd877
ATAI looking to bottom out After closely monitoring psychedelic stocks for approximately six months, my attention has been drawn to ATAI. Despite enduring a challenging period over the past couple of years, the stock appears to be signaling a potential turnaround. Volume Analysis A notable observation is the diminishing volume during each downturn, coupled with a substantial surge in volume in November of the previous year. This pattern indicates a decisive breakout from the prevailing trend. RSI Insights Simultaneously, the Relative Strength Index (RSI) reached its peak at 69. This represents the highest momentum level in the stock's history, signaling increasing strength. This noteworthy event marks the first instance of the weekly RSI surpassing the halfway mark, hinting at the initiation of a potential uptrend. Further supporting this indication is the presence of a bullish RSI divergence. Anticipated Developments My focus is straightforward, with two key criteria: Demand Zone Confirmation ($1.05 - $1.29) Previous High Breakout ($2.23) The occurrence of these events could pave the way for significant upside potential in ATAI, as well as the entire psychedelic industry, with target projections reaching into the double figures.
NASDAQ:ATAILong
by joshuashepherd877
2
$PSIL Bombed out #Weed #ETF $MSOS attacking resistance lines...Will it pull up the AdvisorShares Psychedelics ETF? Strength in the #Biotech sector would also be a friendly situation. here are the top holdings: CMPS COMPASS PATHWAYS PLC 13.12% ATAI ATAI LIFE SCIENCES NV 9.73% CYBN CYBIN INC 7.97% SEEL SEELOS THERAPEUTICS INC 6.90% ITCI INTRA-CELLULAR THERAPIES INC 6.44% HUGE FSD PHARMA INC-CLASS B 5.82% SAGE SAGE THERAPEUTICS INC 5.23% ALKS ALKERMES PLC 4.84% DRUG BRIGHT MINDS BIOSCIENCES INC 4.70% I can see this ETF targeting $3.2 as its first port of call.
AMEX:MSOSLong
by BallaJi
Deeply oversold/undervalued psychedelics playPsychedelics space has seen some multi-baggers in the span of the last 2 weeks, suggesting investors are once again starting to pour money into speculative shroom stocks. CSE:LVT is deeply oversold (RSI @ 22.69), hitting all time lows. The company is deeply fundamentally undervalued: - $1.87M market cap - Raised $1.5M at 0.20 in February - Generating revenue of over $2M per quarter Some comparable psychedelic companies with less revenue are trading at more than 10x. Unless there's some kind of fundamental/unknown reason for recent selloff, other than weak general markets, this is a potential multi-bagger candidate from current levels, in my humble opinion. GLTA
CSE:LVTLong
by agstockpicks
psychedelic is the future for mental healthpsychedelic is the future for mental health. I don't understand why the chart doesn't move but it will be because nothing else can heal the mental illness. At this moment we only have 20 years of Internet. We need to go forward. Psychotherapy doesn't work because sometimes even the client doesn't know what he have. I don't say that compass pathway will be the winner but psychedelic will be. Can you be mindmed medicine, ataiI life science or compass pathway , they are the most biggest market cap in the stock market right now in they category.
NASDAQ:CMPSLong
by CharlesGhavidia
ATAI short-term playHello bulls, This one is a short-term play and can't much be said about it. After CMPS crushed, price dropped to 12$ and then due to Macro economical panic, crabbed around 11$. This is good that it's crabbing around 11$ because the next steps are the slow stairs to the 15$. Volume on last hour of December 3 indicates strong interest in 10.5-11$, meaning any further panic would just keep crabbing the stock. In my opinion, if the stock doesn't close at 13$ by end of December, sell. Because it will not be a short-term swing anymore. My average is 12$, stop loss at 10$. Pros: -Exposure to ATAI assets: 400M cash, 21% stake in CMPS and it's own proper research and development pipeline -Lower the price, higher interest to invest by Dealers or keep their assets protected from too much price fluctuation downward. -Correlation to the Psychedelic sector, specifically CMPS trend. Cons: -No Revenue to backup FA, only assets. -Can't sustain price floor above 11.5$ theses last 3 weeks of bloodbath. Let's hope confidence will be coming back. -Long term not recommended since the company burns cash per quarter. Unless you are investing in speculation. Overall, ATAI resisting to the panic better than BABA. This is not a financial advise and risk should be always taken in count before trading. Take care!
NASDAQ:ATAILong
by DumpItAgain
Possible Wykoff accum. after price discovery - NUMI shroomboomNUMI could be in the midst of a Wykoff accumulation. ^ means a pro, v means a con. I am trying to look at both sides to reduce emotionally-blinded decision making. Looking from far, there is systematic market risk: v institutions adopting Bitcoin, resulting in broad market exposure to USDT fraud risk and Bitcoin volatility v GME apes stressing underlying system A broader market pullback or turn to bear market can affect any stock's price. Looking at the sector: ^ I believe I know that psychedelics work, and are safe ^ mental health a huge industry that impacts all sectors because..humans, and looks to grow due to COVID v proper testing can take time and money v Canadian election can affect the path the sector takes. I believe the psychedelics market is in the nascent stages of a multi-year bull market. Valuing companies in the sector right now is difficult. Looking at the company: ^ one of the few companies in the sector that actually has revenue ^ lower risk of `going to zero` because not focused on novel compounds ^ is focused on creating IP v lower potential to moon because not focused on patenting compounds v rank-ordered within industry, less focused on making money, more focused on helping people and making help accessible ^ outstanding team and network ^ focused on psychedelic-assisted psychotherapy (similar to shamanic-assisted tripping, which is an ancient, proven methodology) ^ $63.2 million cash position (1/3 current market value @~$0.87 ^ YOY revenue is expected to increase by ~100% v not much attention on reddit (hey, it seems to matter) ^ lower volatility due to lack of meme-retail involvement v has diluted shares in the past The company is solid, growing through acquisitions and research, and a leader in the sector. Numinus is licence by Health Canada to cultivate, extract and sell psychedelic compounds. They also have a dealer's licence to import, export, possess, test and distribute MDMA, psilocybin, psilocin, DMT and mescaline. v my understanding is that ibogaine is the most effective psychedelic specifically for opioid addiction. but entails cardiac risk, but numinus does not seem to be working with ibogaine-derived compounds The book: Bear Market Trading Strategies by Matthew R Kratter say that if a stock moves above it's 200 day MA, one can consider shorting. Playing with this logic, NUMI is below it's 200 day MA in what looks to be a possible multi-year bull market, so now might be a good entry point. On morality and ethics: Numinus may not have a 1B valuation like MMED (with 0 revenue), but by supporting a company that is focused on natural healing and accessibility it is a step in a direction away from the big pharma method of `extracting value from` towards the team human (podcast) method of `creating value for`. And I believe that is what the mushrooms want :). How does investing help Numinus Wellness: A higher stock price allows for things such as uplisting to the TSX and NYSE which gives them more access to capital. Also, investor support allows them to obtain capital at a higher valuation. Full disclosure: I bought NUMI at 28c, have sold off portions several time for a variety of reasons, and now am dollar cost averaging in again during sideways movement and am focusing on managing risk. This is my first chart publish. I will appreciate all feedback, critical or otherwise. This is not financial advice.
NLong
by jtorkr
12
Chillin At the 382 FibMNMD still hanging out around this 382 fib line. Wondering if the upcoming Atai IPO will help or hurt things. "Psychadelic penny stocks are performing well as many companies in the niche are growing in both size and popularity. Its latest update comes from May 26th when the company published its first pharmacogenetics data report on LSD in collaboration with Liechti Lab in Basel, Switzerland...Again, the field of psychedelics and publicly traded psychedelic stocks are both very new to investors. However, new can be good if it is done correctly. In the past month, shares of MNMD stock have risen by around 12%. And, in the past year, that number jumps to a staggering 1,143% as of June 16th." Quote Source: 4 Penny Stocks to Watch Following the Fed Meeting and Powell’s Remarks
NASDAQ:MNMD
by PennyStocks101
BETR -- Brought down by .40 PP; rebound likely after flushThis psychedelics play has been selling off after announcing a private placement at .40. Just out of oversold area and close to completing a bullish MACD cross. My guess is that some of the financing participants are selling their .40 shares and keeping the free .50 warrant which creates an opportunity to get in at discount to financing. Management is highly promotional. They managed to run it up 4x following the previous financing. Could see something similar play out, especially if psychedelics sector gets hot again.
CSE:BETRLong
by agstockpicks
Literally The Most Undervalued "Shroom Stock?"I mean look, I know it's all a bunch of speculative mumbo jumbo, but some of these other psychedelic companies have like, BILLION dollar market caps! That's crazy, right? I mean sure, they will certainly disrupt an incredibly-entrenched industry, but it's going to take time for that to happen... That said, I think there are going to be baby steps, which means they're going to work with what they know is effective in the "now." So yeah, ketamine. I'm not a huge fan either, but it's super difficult to ignore it's efficacy in the face of all the facts. I know it's contraindicated for certain individuals, but I still believe there's an avenue for success available for novel formulations. It all looks wacky and appears at first to be pseudoscience, but we're talking about research methods (like PanaceAI) that have been under development for years. It's crazy until it happens, and then it's useful. And it's more than icing on the cake that ketamine is a candidate for the treatment of a whole litany of movement disorders such as ALS. Iiii know, vile, evil drugs are bad and horrible. They'll certainly kill us all, as they always have. But seriously, look into a few things before you scoff at reality. "NMDA receptor antagonist," "parkinson's LID ketamine," "ketamine glutamate." Oh, I mentioned market caps. There's a fundamental reason to pay close attention here: as of right now (5/2/21), it's looking like a little north of $14 million USD. The company already had a pre-IND meeting with the FDA regarding their first Phase II trial, and as noted in the chart, the announcement was made on 4/20. For those that aren't aware, this means that the company will be permitted to commence their trials as soon as 5/21, provided that the FDA does not deny the IND request. 8 sites, up to 36 patients.. based on "no-brainer" data. Catalyst one. Let me know how wrong I am about this, please. I am begging you to give me a counterpoint here, because I've dug and dug and haven't found it yet.
OTC:PHRRFLong
by pleasesendhel
MMED about to get a big catalystHello bull gang and bagholders, after long 6 months of bagholding, the NASDAQ uplisting is around the corner. On 3/30/2021, after market, MMED released a news about filing form F-10 with SEC, which will give them the ability to sell securities in USA. Also, on April 12, MMED will uphold a vote and any investor who holds MMED or MMEDF shares will be able to vote, this is obvious that the vote is about NASDAQ uplisting because they cannot uplist our shares on another exchange without our permission. I am in full support to uplist the shares on NASDAQ and once the vote is passed and majority agrees to uplist, it will trigger a catalyst and the price easily can hit 7-10$ on the hype. I also think that on the uplisting day, the shares can go up in price because of retail to Robinhood traders. At last, we finally rise up to the skies. However, please consider risk and do your own DD before buying as this is my own opinion and speculation. Thanks gang.
MLong
by DumpItAgain
1
TRIP.C is starting another leg up on Brazil expansion newsTRIP had a major news release today, having its psychedelic products authorized for import to Brazil. The stock has consolidated well and is forming a Double Bottom (bullish biased) pattern on the daily chart. Promotional campaign is under way. I am in at .495. -- Red Light Holland iMicrodose Pack Receives Authorization for the First Legal Import and Sale of Psilocybin Truffles to Brazil Anvisa, The Brazilian Health Regulatory Agency has granted a permit to import the Company's iMicrodose Pack by way of the Country's 'named patient import process' for prescribed medical use Toronto, Ontario--(Newsfile Corp. - February 25, 2021) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands, is extremely pleased to announce that Anvisa, Brazil's National Health Regulatory Agency, has granted authorization for the Company's iMicrodose packs, which contain 15g of Psilocybin Truffles, to be legally imported to Brazil via the 'named patient import process' for prescribed medical patient use. "We are grateful for our collaborative relationship with Disruptive Pharma who worked closely with the Brazilian Health Regulatory Agency to secure authorization to import Red Light Holland's iMicrodose packs, with our natural-occurring branded Psilocybin Truffles, to be imported and sold in Brazil for Medical use, as our branded iMicrodose packs have officially been prescribed by a doctor to a patient in Brazil," said Todd Shapiro, CEO and Director of Red Light Holland. "This is a monumental day for the Company, and we are so proud to be a part of providing legal access of psilocybin to Brazil and for the first time having our product prescribed by a physician for medical use." Red Light Holland's iMicrodose packs have been shipped to Disruptive Pharma's MyPharma2Go logistics hub in the Netherlands to start their journey to Brazil. Once landed in Brazil, MyPharma2Go is expected to deliver the iMicrodose packs to a Brazilian patient as they have been pre-prescribed by a physician, before the end of March 2021. This approval and shipment represent a significant advancement in opening the legal and medically approved market for psilocybin in Brazil, a country with a population of over 200 million people. Shapiro added: "This early process working alongside Disruptive Pharma's MyPharma2Go.com, a large Brazilian online pharmaceutical and supplement distributor, has been an absolute pleasure and one we are thankful for. We are pleased to do our part to potentially be a part of positive change in Brazil, and to steal a line from Neil Armstrong: This is one micro step for man, one macro leap for mankind." Red Light Holland and Disruptive Pharma continue to work towards finalizing their proposed joint venture structure and agreement, as previously disclosed in the Company's news release dated December 14, 2020. In consideration for Disruptive Pharma having met these initial milestones, the Company has agreed to issue to Disruptive Pharma, 3,000,000 common share purchase warrants, each warrant is exercisable into one common share of the Company at a price of $0.50 per share for a period of 2 years. 750,000 of these warrants have vested immediately based on Disruptive Pharma having fulfilled these milestones, the balance vest upon future milestones being met. These warrants and any underlying shares issued upon exercise, are subject to a statutory hold period of 4 months and 1 day.
CSE:TRIP
by agstockpicks
5